CHRONIC MYELOMONOCYTIC LEUKEMIA-2
Clinical trials for CHRONIC MYELOMONOCYTIC LEUKEMIA-2 explained in plain language.
Never miss a new study
Get alerted when new CHRONIC MYELOMONOCYTIC LEUKEMIA-2 trials appear
Sign up with your email to follow new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA-2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can adding another drug improve MDS treatment?
Disease control OngoingThis study compares the standard drug azacitidine alone versus azacitidine combined with either lenalidomide or vorinostat in 282 patients with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The goal is to see if any combination improves re…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA-2
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo aims to control Hard-to-Treat leukemia
Disease control OngoingThis study tests a combination of two drugs—tagraxofusp and decitabine—in people with chronic myelomonocytic leukemia or high-risk myelodysplastic syndromes. Tagraxofusp is a targeted therapy that delivers a toxin to cancer cells, while decitabine is a chemotherapy drug. The tria…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA-2
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug duo targets hard-to-treat blood cancers
Disease control OngoingThis study tests a new drug, seclidemstat, combined with a standard drug, azacitidine, for people with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The goal is to find the best dose and see if the combination can shrink or control the cancer. About 2…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA-2
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC